Recent Advances in Biological Research on Prostate Cancer

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Cancer Biology".

Deadline for manuscript submissions: 31 May 2026 | Viewed by 84

Special Issue Editors


E-Mail Website
Guest Editor
Centre for Quality of Health and Living (CQHL), Faculty of Health and Environmental Sciences, Central University of Technology, Free State, Bloemfontein 9301, South Africa
Interests: cancer; molecular biology; pharmacology; toxicity
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Health Sciences, Faculty of Health and Environmental Sciences, Central University of Technology, Free State, Bloemfontein 9301, South Africa
Interests: molecular biology; molecular typing; toxicity; antimicrobial activity; antioxidant determinations; bacterial profiling; diseases monitoring; sensitivity testing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce a call for submissions for an upcoming Special Issue focusing on the “Advances in Biological Research of Prostate Cancer”. Prostate cancer remains one of the most prevalent and challenging health issues globally, demanding continual exploration of its biological intricacies, innovative diagnostics, and targeted treatments. As the landscape of cancer research evolves, we invite scholars and experts from diverse backgrounds to contribute their valuable insights to this significant field.

The aim of this Special Issue is to capture the latest advancements, breakthroughs and research findings related to the biological aspects of prostate cancer. We welcome original research articles, reviews and methodological papers addressing, but not limited to, the following topics:

  1. Molecular Mechanisms: Exploration of genetic and epigenetic factors contributing to prostate cancer development and progression.
  2. Biomarkers: Identification and validation of novel biomarkers for early detection, prognosis, and monitoring of prostate cancer.
  3. Therapeutic Targets: Insights into potential therapeutic targets, immunotherapeutic approaches, and personalized treatments for prostate cancer patients.
  4. Microenvironment and Metastasis: Studies elucidating the role of the tumor microenvironment, angiogenesis, and metastatic pathways in prostate cancer.
  5. Precision Medicine: Advances in precision medicine techniques, including genomics, proteomics, and imaging technologies, for prostate cancer diagnosis and treatment.
  6. Therapeutic Resistance: Understanding the mechanisms of therapeutic resistance and exploring strategies to overcome resistance in prostate cancer therapies.

We look forward to receiving your contributions.

Prof. Dr. Samson Mashele
Dr. Pakiso Makhoahle
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • biological research
  • molecular mechanisms
  • biomarkers
  • precision medicine
  • therapeutic targets
  • tumor microenvironment
  • therapeutic resistance
  • genomics
  • quality of life

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 4362 KiB  
Review
Bolstering CD8+ T Cells’ Antitumor Immunity: A Promising Strategy to Improve the Response to Advanced Prostate Cancer Treatment
by Beijing Dang, Lixin Liang, Zhijun Li, Junli Luo and Shangwei Zhong
Biology 2025, 14(5), 544; https://doi.org/10.3390/biology14050544 - 14 May 2025
Abstract
Prostate cancer is among the most frequently diagnosed and deadly cancers among men in the Western world. It is typically classified as an immune “cold” tumor due to its sparse immune cell presence and limited immunogenic response. Recent research has revealed the significant [...] Read more.
Prostate cancer is among the most frequently diagnosed and deadly cancers among men in the Western world. It is typically classified as an immune “cold” tumor due to its sparse immune cell presence and limited immunogenic response. Recent research has revealed the significant role of immune cells, especially CD8+ T cells, in both prostate cancer progression and treatment efficacy. This review integrates recent findings to provide a comprehensive overview of the current understanding of CD8+ T cell dynamics in prostate cancer and discusses emerging strategies to improve treatment outcomes. The ongoing exploration of new molecular targets and the development of innovative immunotherapeutic approaches hold promise for more effective management of prostate cancer, particularly in the context of advanced and resistant forms of the disease. Full article
(This article belongs to the Special Issue Recent Advances in Biological Research on Prostate Cancer)
Show Figures

Figure 1

Back to TopTop